In vivo experiments suggested that blockade of PD-1 signaling with anti-PD-L1 or anti-PD-1 monoclonal antibody promoted CD8+ T cells infiltration into the tumor, induced local immune activation, and finally resulted in substantial anti-tumor effects in a murine pancreatic cancer model [105]. Here, PDCD1 is linked to familial pancreatic carcinoma.